Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amifostine for Prevention of Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma
ChiCTR-TCC-12002759Phase 4Completed
- Sponsor
- Department of Hematology, First Affiliated Hospital of Dalian Medical University
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of amifostine in multiple myeloma (MM) and peripheral neuropathy (2 arms), sponsored by Department of Hematology, First Affiliated Hospital of Dalian Medical University. Primary endpoints: Grade of peripheral neuropathy, Serum M-protein quantitation and 5 more. Started Jan 2011; status: completed.
02
Drugs
amifostine
03
Conditions
multiple myeloma (MM)peripheral neuropathy
Beyond the preview
Go deeper on ChiCTR-TCC-12002759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TCC-12002759.